Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2006

View Archived Issues

YM-341619: novel STAT-6 inhibitor with efficacy against allergy

University of Arizona presents a novel bifunctional opioid agonist/NK-1 antagonist

Antiendotoxic effects of a novel polymyxin B analogue

Evidence connects chemokines and their receptors with lung metastasis

Alnylam's pandemic influenza research boosted by NIAID grant

Intercell and Path team up for S. pneumoniae vaccine

SBIR grant for Cleveland BioLabs' radioprotector research

MethylGene report on enhanced potency of second generation MGCD-0103 analogues

Artisan Pharma formed through financing and compound inlicensing

p53/p21 status regulates the response to VX-680

Italian researchers present a novel selective muscarinic M3 receptor antagonist

Dual dopamine D2/D3 receptor ligand described with antipsychotic efficacy

European orphan designation for Advexin in Li-Fraumeni syndrome

Ipsen and GTx sign European agreement for Acapodene rights

Phase IIb studies in Denmark to assess BP-C1 for breast cancer

Taisho and Tokuhon collaborate on antiinflammatory analgesic patch in Japan

Takara Bio offers RetroNectin for phase I CLL trials

AnGes plans atopic dermatitis trial for NF-kappaB decoy oligodeoxynucleotide

Northwest cleared for phase I study of DCVax-LB in NSCLC

Xoma successfully reformulates XOMA-629 for acne

New ARIES-3 study investigates ambrisentan in pulmonary hypertension

Chelsea seeks orphan drug status, forms scientific advisory board for droxidopa

Teverelix LA shows potential for endometriosis

Novel antiinfective agents disclosed in recent patent literature

Symlin improves diabetes control in study

Recent patents disclose new therapeutic agents for depression, insomnia

Novel diagnostic agents emerge from Mallinckrodt R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...